Objectif
HIV-1 and AIDS are spreading in Africa and Asia at unprecedented speed. A vaccine against HIV-1/AIDS is urgently needed. Vaccine candidates that show most promise in simian AIDS models are based on a prime-boost strategy, applying naked DNA or alphaviruses as prime and pox viruses as boost. The objectives of the EuroVac- II project are to demonstrate in a phase I trial of humans: firstly the ability of Semliki Forest virus (SFV) to prime anti-HIV immune responses, - compared to the attenuated poxvirus NYVAC -, using a recombinant gp140 protein boost; and secondly the ability of SFV priming, - using DNA priming as benchmark -, to improve the immune responses elicited by NYVAC + rgp140 vaccination. This design will provide conclusions concerning the relative immunogenicity of different prime-boost strategies. The HIV-1 genes used are recovered from a primary isolate belonging to HIV-1 subtype C, the most frequent cause of AIDS worldwide. The choice of genes (gag, pol, nef) other than envelope is based on the frequency of HIV-specific T-cell responses in long-term asymptomatic HIV infected individuals.
Champ scientifique
CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN.
CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN.
- natural sciencesbiological sciencesmicrobiologyvirology
- natural sciencesbiological sciencesgeneticsDNA
- medical and health sciencesbasic medicineimmunology
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesHIV
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
Appel à propositions
Data not availableRégime de financement
DEM - Demonstration contractsCoordinateur
171 77 Stockholm
Suède